December 11, 2024 (Oakville, ON) – The Coordinated Accessible National (CAN) Health Network is excited to welcome DeCell Technologies, a Halifax-based biomedical company specializing in advanced wound care solutions.
As diabetes rates continue to rise, diabetic foot ulcers – a major complication of the disease – are placing an increasing strain on the Canadian health care system. Affecting 15 to 25 per cent of people with diabetes, these chronic wounds are often difficult to heal. The current standard of care has only a 50 per cent healing rate after 12 weeks of treatment. In severe cases, 80 per cent of patients with untreated or poorly managed diabetic foot ulcers will require a lower limb amputation, contributing to poor patient outcomes and an increased burden on the healthcare system.
DeCell Technologies’ innovative product, DermGEN™, offers a promising solution for treating diabetic foot ulcers. Designed to accelerate healing, DermGEN has shown an 80 per cent success rate in healing diabetic foot ulcers in just four weeks. This advanced wound care product has the potential to significantly improve patient outcomes by reducing the risk of amputations, hospitalizations, and emergency visits, while also lowering overall health care costs.
Through its partnership with the CAN Health Network, DeCell Technologies is collaborating with Nova Scotia Health and the Health Innovation Hub on a commercialization project to implement DermGEN in clinics and hospitals across the province. This partnership is offering hope for faster healing times and improved quality of life for patients living with diabetic foot ulcers.
Sign up for email
Error: Contact form not found.